{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:30:58Z","timestamp":1791325858697,"version":"4.3.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Modified Vaccinia Ankara (MVA) was recently approved as a smallpox vaccine. Variola is transmitted by respiratory droplets and MVA immunization by skin scarification (s.s.) protected mice far more effectively against lethal respiratory challenge with vaccinia virus (VACV) than any other route of delivery, and at lower doses. Comparisons of s.s. with intradermal, subcutaneous, or intramuscular routes showed that MVA\n                    <jats:sub>OVA<\/jats:sub>\n                    s.s.-generated T cells were both more abundant and transcriptionally unique. MVA\n                    <jats:sub>OVA<\/jats:sub>\n                    s.s. produced greater numbers of lung Ova-specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>RM<\/jats:sub>\n                    and was superior in protecting mice against lethal VACV\n                    <jats:sub>OVA<\/jats:sub>\n                    respiratory challenge. Nearly as many lung T\n                    <jats:sub>RM<\/jats:sub>\n                    were generated with MVA\n                    <jats:sub>OVA<\/jats:sub>\n                    s.s. immunization compared to intra-tracheal immunization with MVA\n                    <jats:sub>OVA<\/jats:sub>\n                    and both routes vaccination protected mice against lethal pulmonary challenge with VACV\n                    <jats:sub>OVA<\/jats:sub>\n                    . Strikingly, MVA\n                    <jats:sub>OVA<\/jats:sub>\n                    s.s.-generated effector T cells exhibited overlapping gene transcriptional profiles to those generated via intra-tracheal immunization. Overall, our data suggest that heterologous MVA vectors immunized via s.s. are uniquely well-suited as vaccine vectors for respiratory pathogens, which may be relevant to COVID-19. In addition, MVA delivered via s.s. could represent a more effective dose-sparing smallpox vaccine.\n                  <\/jats:p>","DOI":"10.1038\/s41541-020-00265-5","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T06:02:41Z","timestamp":1609740161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge"],"prefix":"10.1038","volume":"6","author":[{"given":"Youdong","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-1201","authenticated-orcid":false,"given":"Chang Ook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena Y.","family":"Lofftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire A.","family":"Stingley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-2916","authenticated-orcid":false,"given":"Thomas S.","family":"Kupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"265_CR1","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/S0264-410X(99)00434-X","volume":"18","author":"MR Hilleman","year":"2000","unstructured":"Hilleman, M. R. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 18, 1436\u20131447 (2000).","journal-title":"Vaccine"},{"key":"265_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00006454-199902000-00002","volume":"18","author":"M Radetsky","year":"1999","unstructured":"Radetsky, M. Smallpox: a history of its rise and fall. Pediatr. Infect. Dis. J. 18, 85\u201393 (1999).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"265_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2217\/fmb.15.19","volume":"10","author":"AS Bandyopadhyay","year":"2015","unstructured":"Bandyopadhyay, A. S., Garon, J., Seib, K. & Orenstein, W. A. Polio vaccination: past, present and future. Future Microbiol. 10, 791\u2013808 (2015).","journal-title":"Future Microbiol."},{"key":"265_CR4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1542\/peds.81.2.237","volume":"81","author":"A Deforest","year":"1988","unstructured":"Deforest, A. et al. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 81, 237\u2013246 (1988).","journal-title":"Pediatrics"},{"key":"265_CR5","doi-asserted-by":"publisher","first-page":"253ps211","DOI":"10.1126\/scitranslmed.3009848","volume":"6","author":"WA Orenstein","year":"2014","unstructured":"Orenstein, W. A., Seib, K., Graham-Rowe, D. & Berkley, S. Contemporary vaccine challenges: improving global health one shot at a time. Sci. Transl. Med. 6, 253ps211 (2014).","journal-title":"Sci. Transl. Med."},{"key":"265_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/COH.0000000000000362","volume":"12","author":"J Pollara","year":"2017","unstructured":"Pollara, J., Easterhoff, D. & Fouda, G. G. Lessons learned from human HIV vaccine trials. Curr. Opin. HIV AIDS 12, 216\u2013221 (2017).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"265_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-med-120611-145115","volume":"64","author":"N Pica","year":"2013","unstructured":"Pica, N. & Palese, P. Toward a universal influenza virus vaccine: prospects and challenges. Annu. Rev. Med. 64, 189\u2013202 (2013).","journal-title":"Annu. Rev. Med."},{"key":"265_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","volume":"20","author":"MD Tapia","year":"2020","unstructured":"Tapia, M.D. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 20, 719\u2013730 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"265_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.idc.2019.07.001","volume":"33","author":"DSC Hui","year":"2019","unstructured":"Hui, D. S. C. & Zumla, A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect. Dis. Clin. North Am. 33, 869\u2013889 (2019).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"265_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0170-0","volume":"5","author":"W Shang","year":"2020","unstructured":"Shang, W., Yang, Y., Rao, Y. & Rao, X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines 5, 18 (2020).","journal-title":"NPJ Vaccines"},{"key":"265_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nm.2078","volume":"16","author":"L Liu","year":"2010","unstructured":"Liu, L. et al. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat. Med. 16, 224\u2013227 (2010).","journal-title":"Nat. Med."},{"key":"265_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41577-019-0162-3","volume":"19","author":"AW Ho","year":"2019","unstructured":"Ho, A. W. & Kupper, T. S. T cells and the skin: from protective immunity to inflammatory skin disorders. Nat. Rev. Immunol. 19, 490\u2013502 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"265_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1128\/CMR.3.2.153","volume":"3","author":"DE Hruby","year":"1990","unstructured":"Hruby, D. E. Vaccinia virus vectors: new strategies for producing recombinant vaccines. Clin. Microbiol. Rev. 3, 153\u2013170 (1990).","journal-title":"Clin. Microbiol. Rev."},{"key":"265_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3121\/cmr.1.2.87","volume":"1","author":"EA Belongia","year":"2003","unstructured":"Belongia, E. A. & Naleway, A. L. Smallpox vaccine: the good, the bad, and the ugly. Clin. Med. Res. 1, 87\u201392 (2003).","journal-title":"Clin. Med. Res."},{"key":"265_CR15","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1128\/JVI.00264-12","volume":"86","author":"E Guzman","year":"2012","unstructured":"Guzman, E. et al. Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation. J. Virol. 86, 5452\u20135466 (2012).","journal-title":"J. Virol."},{"key":"265_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1006\/viro.1998.9123","volume":"244","author":"G Antoine","year":"1998","unstructured":"Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365\u2013396 (1998).","journal-title":"Virology"},{"key":"265_CR17","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","volume":"381","author":"PR Pittman","year":"2019","unstructured":"Pittman, P. R. et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. N. Engl. J. Med. 381, 1897\u20131908 (2019).","journal-title":"N. Engl. J. Med."},{"key":"265_CR18","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1055\/s-0028-1108143","volume":"99","author":"H Stickl","year":"1974","unstructured":"Stickl, H. et al. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author\u2019s transl)]. Dtsch Med. Wochenschr. 99, 2386\u20132392 (1974).","journal-title":"Dtsch Med. Wochenschr."},{"key":"265_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1086\/651560","volume":"201","author":"MS Seaman","year":"2010","unstructured":"Seaman, M. S. et al. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J. Infect. Dis. 201, 1353\u20131360 (2010).","journal-title":"J. Infect. Dis."},{"key":"265_CR20","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","volume":"31","author":"MG Cottingham","year":"2013","unstructured":"Cottingham, M. G. & Carroll, M. W. Recombinant MVA vaccines: dispelling the myths. Vaccine 31, 4247\u20134251 (2013).","journal-title":"Vaccine"},{"key":"265_CR21","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/v6072735","volume":"6","author":"AF Altenburg","year":"2014","unstructured":"Altenburg, A. F. et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6, 2735\u20132761 (2014).","journal-title":"Viruses"},{"key":"265_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/infdis\/jiq164","volume":"203","author":"M Bray","year":"2011","unstructured":"Bray, M. Understanding smallpox vaccination. J. Infect. Dis. 203, 1037\u20131039 (2011).","journal-title":"J. Infect. Dis."},{"key":"265_CR23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/infdis\/jiq162","volume":"203","author":"SN Gordon","year":"2011","unstructured":"Gordon, S. N. et al. Smallpox vaccine safety is dependent on T cells and not B cells. J. Infect. Dis. 203, 1043\u20131053 (2011).","journal-title":"J. Infect. Dis."},{"key":"265_CR24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1086\/423848","volume":"190","author":"JS Kennedy","year":"2004","unstructured":"Kennedy, J. S. et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J. Infect. Dis. 190, 1286\u20131294 (2004).","journal-title":"J. Infect. Dis."},{"key":"265_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fcimb.2012.00150","volume":"2","author":"DK Milton","year":"2012","unstructured":"Milton, D. K. What was the primary mode of smallpox transmission? Implications for biodefense. Front. Cell Infect. Microbiol. 2, 150 (2012).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"265_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.humimm.2005.12.004","volume":"67","author":"M Terajima","year":"2006","unstructured":"Terajima, M. et al. Identification of vaccinia CD8+ T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Hum. Immunol. 67, 512\u2013520 (2006).","journal-title":"Hum. Immunol."},{"key":"265_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-019-0928-6","volume":"566","author":"JB Eaglesham","year":"2019","unstructured":"Eaglesham, J. B., Pan, Y., Kupper, T. S. & Kranzusch, P. J. Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS-STING signalling. Nature 566, 259\u2013263 (2019).","journal-title":"Nature"},{"key":"265_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149364","volume":"11","author":"CA Meseda","year":"2016","unstructured":"Meseda, C. A., Atukorale, V., Kuhn, J., Schmeisser, F. & Weir, J. P. Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines. PLoS ONE 11, e0149364 (2016).","journal-title":"PLoS ONE"},{"key":"265_CR29","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1086\/651561","volume":"201","author":"MB Wilck","year":"2010","unstructured":"Wilck, M. B. et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J. Infect. Dis. 201, 1361\u20131370 (2010).","journal-title":"J. Infect. Dis."},{"key":"265_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature21379","volume":"543","author":"Y Pan","year":"2017","unstructured":"Pan, Y. et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature 543, 252\u2013256 (2017).","journal-title":"Nature"},{"key":"265_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1056\/NEJM200010053431407","volume":"343","author":"UH von Andrian","year":"2000","unstructured":"von Andrian, U. H. & Mackay, C. R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med 343, 1020\u20131034 (2000).","journal-title":"N. Engl. J. Med"},{"key":"265_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nri1310","volume":"4","author":"TS Kupper","year":"2004","unstructured":"Kupper, T. S. & Fuhlbrigge, R. C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4, 211\u2013222 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"265_CR33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nm.3883","volume":"21","author":"CO Park","year":"2015","unstructured":"Park, C. O. & Kupper, T. S. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat. Med. 21, 688\u2013697 (2015).","journal-title":"Nat. Med."},{"key":"265_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.cell.2017.08.024","volume":"171","author":"M Kadoki","year":"2017","unstructured":"Kadoki, M. et al. Organism-level analysis of vaccination reveals networks of protection across tissues. Cell 171, 398\u2013413. e321 (2017).","journal-title":"Cell"},{"key":"265_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088340","volume":"9","author":"A Hessel","year":"2014","unstructured":"Hessel, A. et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS ONE 9, e88340 (2014).","journal-title":"PLoS ONE"},{"key":"265_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.vaccine.2004.05.015","volume":"23","author":"W Olszewska","year":"2004","unstructured":"Olszewska, W., Suezer, Y., Sutter, G. & Openshaw, P. J. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23, 215\u2013221 (2004).","journal-title":"Vaccine"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00265-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T18:26:13Z","timestamp":1670005573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00265-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["265"],"URL":"https:\/\/doi.org\/10.1038\/s41541-020-00265-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.06.079046","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.S.K. and L.L. are inventors on a patent relevant to this study (US8691502B2). The patent is now owned by Pellis Therapeutics, a biotech company, in which T.S.K. and L.L. have equity. T.S.K. has received supplemental funding from the NIAID to study MVA s.s immunization with constructs encoding SARS CoV2 proteins, including Spike (R01 AI127654).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}